Brief: Axsome Therapeutics Announces Availability Of Symbravo® For The Acute Treatment Of Migraine
10/06/2025 12:11
June 10 (Reuters) - Axsome Therapeutics Inc AXSM.O: AXSOME THERAPEUTICS ANNOUNCES AVAILABILITY OF SYMBRAVO® (MELOXICAM AND RIZATRIPTAN) FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS Source text: ID:nGNX3NWV0r Further company coverage: AXSM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axsome Therapeutics
See all newsUS RESEARCH ROUNDUP-Bright Minds Biosciences, Marvell Technology, Oracle Corporation
Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi
US RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Axsome Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Axsome Therapeutics Q2 revenue rises on AUVELITY growth